Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan hydrochloride tablet pharmacokinetic and safety study in subjects with renal impairment
CTR20244080Phase 4Completed
- Sponsor
- 江苏柯菲平医药股份有限公司/ 南京柯菲平盛辉制药有限公司
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of keverprazan in erosive esophagitis (EE), duodenal ulcer, sponsored by 江苏柯菲平医药股份有限公司/ 南京柯菲平盛辉制药有限公司. Started Jan 2025; status: completed.
02
Drugs
keverprazan
03
Conditions
erosive esophagitis (EE)duodenal ulcer
Beyond the preview
Go deeper on CTR20244080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244080.